What Cindy Eckert has planned with Sprout, Addyi back in hands

It ’s take two for Sprout Pharmaceuticals and Addyi, the only drug approved by the U.S. Food and Drug Administration to treat low sexual desire disorder in women.  With Sprout back in its former shareholder hands from Valeant Pharmaceuticals (NYSE: VRX), and former CEO Cindy Eckert (formerly Whiteh ead) back at its helm, Addyi relaunched Monday from its previous base in the CapTrust Tower at North Hills. “The baby is back, and I’m making some radical changes,” Eckert says. “This has always…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news